

## ACRUX ANNOUNCES FDA DRUG SAFETY COMMUNICATION CALL

Acrux (ASX: ACR) today confirmed a call on the FDA Drug Safety Communication for all investors on Wednesday 4 March 2015 at 11am.

Investors are now welcome to register for this event via our website [www.acrux.com.au](http://www.acrux.com.au) under the Investors tab or via the attached link <https://event.on24.com/eventRegistration/EventLobbyServlet?target=registration.jsp&eventid=962043&sessionid=1&key=84293AA931DAFB27E6BF39E7D372F7&sourcepage=register>

### Contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

### About Acrux

[www.acrux.com.au](http://www.acrux.com.au)

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology.
- The Acrux technology, used in marketed products including Axiron®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.
- Acrux has three products marketed by licensees in the USA, three products approved in

Europe, and further products at earlier stages of development.